These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17013993)

  • 1. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine advance-purchase agreements for low-income countries: practical issues.
    Berndt ER; Hurvitz JA
    Health Aff (Millwood); 2005; 24(3):653-65. PubMed ID: 15886157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicine. The intangible value of vaccination.
    Rappuoli R; Miller HI; Falkow S
    Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced purchase commitments for a malaria vaccine.
    Natl Bur Econ Res Bull Aging Health; 2005; (12):1-2. PubMed ID: 16175672
    [No Abstract]   [Full Text] [Related]  

  • 8. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European strategy for vaccine development against infectious diseases.
    Matthiessen L; Lång H; Klimathianaki M; Hanrahan F; Kerstiëns B; Martini A; Draghia-Akli R
    Vaccine; 2017 Jan; 35 Suppl 1():A20-A23. PubMed ID: 28017443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Towards a new vaccine economy?].
    Poirot P; Martin JF
    Sante; 1994; 4(3):183-7. PubMed ID: 7921683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.
    Towse A; Kettler H
    Bull World Health Organ; 2005 Apr; 83(4):301-7. PubMed ID: 15868022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How the research-based industry approaches vaccine development and establishes priorities.
    André FE
    Dev Biol (Basel); 2002; 110():25-9. PubMed ID: 12477303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria.
    Plebanski M; Lopez E; Proudfoot O; Cooke BM; Itzstein Mv; Coppel RL
    Methods; 2006 Sep; 40(1):77-85. PubMed ID: 16997716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.